Amazon Pharmacy recently launched a new caregiver feature and expanded PillPack to Medicare Part D. The company says the updates will support medication adherence.
Medicare Part D spending on 10 diabetes drugs increased 364% between 2019 and 2023.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
The average total monthly premium for Medicare Part D coverage is expected to be $55.50 in 2024, down from $56.49 in 2023, according to CMS.
KFF found that the 10 top-selling Part D drugs represented $47.7 billion of the $215.7 billion total gross Medicare Part D drug spending in 2021. Eliquis, a blood thinner by Bristol Myers Squibb, accounted for the most spending out of these 10 drugs at $12.6 billion.
The average monthly premium for Medicare Advantage plans increased to $7 in the first half of the Medicare Annual Open Enrollment period this year, the eHealth report found. Premiums were in the $4 to $5 range for the last three years.
There are 260 MA plans with Part D coverage that received four stars or more for 2023, a share of about 51%. This is a steep decline from 2022, when there were 322 plans with four stars or more, accounting for about 68% of plans.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Over 1 million Medicare beneficiaries had a diagnosis for opioid use disorder in 2021. But despite this high number, only 18% received medication to treat their disorder.
Confidentiality agreements typically prevent the public from obtaining a window into the cases against pharmacy behemoths but a public court filing makes this one different.
More than 1,750 Medicare part D plans and Medicare Advantage plans will limit out-of-pocket insulin costs to a $35 copay next year. The change would make patients' out-of-pocket costs more consistent than the current system, where payments fluctuate in different stages of their Part D plan.
Regulatory approval for the purchase is predicated on Aetna's previously announced plans to sell off its Medicare Part D business to WellCare Health.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
"Aetna believes the Divestiture is a significant step toward completing the DOJ’s review of the CVS Health Transaction," the company wrote in its SEC filing.
This represents the president's second change of opinion on the matter in the last week.
The abrupt rise is notable because many people think that life-threatening allergies are less common among the elderly. In addition, epinephrine — the active ingredient in EpiPens — can pose greater risks to older adults.
Spending on these medications in Medicare’s Part D program, for example, rose 56 percent last year, with some of the costliest products, including topical pain creams, priced at hundreds or thousands of dollars per tube.
The study, which appears in Health Affairs, is the first to examine whether legalization changes doctors’ clinical practice and whether it could curb public health costs.